Cadence Molecular Sciences (OpenEye)—a business unit of Cadence (Nasdaq: CDNS)—has agreed to provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.
![asap_logo_shield_12-22[25]](https://www.eyesopen.com/hs-fs/hubfs/asap_logo_shield_12-22%5B25%5D.jpg?width=480&height=552&name=asap_logo_shield_12-22%5B25%5D.jpg){kind=logo}
The $68M National Institutes of Health Grant was awarded to Chodera Lab to develop their AI-driven Structure-enabled Antiviral Platform (ASAP). ASAP is designed to build on the successes of the COVID Moonshot, a global, open-science collaboration that began in March 2020 and rapidly identified potent antivirals targeting the main protease of the SARS-CoV-2 virus.
Read the full news release here.
For media inquiries, please contact newsroom@cadence.com